HomeAI · summaries
Storia in 4 fonti
Novartis Heart Drug Failure Rattles Market for Rival Treatments
(Bloomberg) -- Few new ideas in heart-drug research appeared to have as much going for them as Lp(a).
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
- ·
qz.com
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
